2025-05-01
In 2024, Merck’s Keytruda continued its reign with nearly $29.5 billion in sales, posting solid 17.9% growth over 2023. However, the pharmaceutical landscape is shifting rapidly. The combined forces of GLP-1 receptor agonists used for diabetes and weight loss are mounting a serious challenge; Novo Nordisk’s Ozempic surged 25.8% to $17.5 billion, its sibling Wegovy grew 83%, and Eli Lilly’s Mounjaro exploded with 123.5% growth to reach $11.5 billion. Keytruda’s looming patent expiry further cloud
